In 553 adults with moderate-to-severe asthma on BDP/FF/G pMDI, switching to the low global warming potential HFA-152a propellant vs staying on HFA-134a did not differ in FEV1 change 10 min post-dose (−1.143%); adverse events 19.3% vs 27.6%.
RCTn = 553
Singh et al. Safety and tolerability of the low global warming potential propellant HFA-152a in patients with asthma receiving beclometasone dipropionate/formoterol fumarate/glycopyrronium: The TRECOS study